Specialized hospital care associated with better survival in Dutch ovarian cancer patients

March 11, 2008

Dutch ovarian cancer patients who were treated at a semispecialized or specialized hospital survived longer than those treated at a general hospital, according to a study published online March 11 in the Journal of the National Cancer Institute.

Several studies have suggested that concentrating ovarian cancer care at regional centers improves patient outcomes. The necessity of such an approach in The Netherlands was unknown. The Dutch system already allows for collaboration between specialized and general gynecologists.

Flora Vernooij, M.D., of the University Medical Center Utrecht in The Netherlands and colleagues conducted a retrospective study of all of the ovarian cancer patients treated in The Netherlands between 1996 and 2003.

Of 8,621 women diagnosed with ovarian cancer, 40 percent were treated in general hospitals, 41 percent in semispecialized hospitals, and 18 percent in specialized centers. The estimated five year survival improved with increasing specialization of the treatment facility, from 38 percent to 39.4 percent and 40.3 percent, respectively. The difference was statistically significant for women between the ages of 50 and 75 years who were diagnosed with early cancer. Their risk of death due to ovarian cancer dropped by 30 percent and 42 percent following treatment at a semispecialized and specialized hospital, relative to treatment at a general hospital.

“This result indicates that the level of collaboration during the study period did not suffice to deliver optimal care to all Dutch ovarian cancer patients, and regionalization of the care for such patients thus seems necessary,” the authors write.

In an accompanying editorial, Deborah Schrag, M.D., of the Dana-Farber Cancer Institute in Boston argues that while population-based studies that correlate patterns of care and clinical outcomes are important, they must be interpreted with caution. Confounding variables and information that is not tracked in such data sets could lead to inaccurate conclusions.

For example, in the study by Vernooij and colleagues, the patients treated at general hospitals appear to differ from those treated at specialized centers in terms of age and the types of treatment they underwent. Moreover, information about patients’ comorbidity and performance status was not available. “Therefore, this analysis in and of itself does not justify regionalization of ovarian cancer surgery in The Netherlands to specialty centers,” she writes.

To allow for more valuable analyses, Schrag calls for an expansion of the types of information cancer registries collect. “As the number of cancer therapies increases and as the need to systematically evaluate their real-world clinical effectiveness grows, there is a need to optimize the data that can be gleaned from observational data sources,” she writes. “A compelling case can be made for expanding the scope of data that tumor registries collect.”

Source: Journal of the National Cancer Institute

Explore further: Who might benefit from immunotherapy? New study suggests possible marker

Related Stories

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

How can CRISPR genome editing shape the future of cancer research?

January 12, 2018
The genome editing technology CRISPR is causing plenty of excitement in cancer research.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.

Novel combination therapy shown to be effective in ovarian cancer

December 19, 2017
Researchers at The Wistar Institute have found that combining PARP inhibitors, recently approved for the treatment of BRCA-mutant ovarian cancer, with another small molecule inhibitor was effective to treat ovarian cancers ...

Targeting cancer by sabotaging the DNA repair seesaw

January 3, 2018
A protein that cancer cells rely on to stave off cell death also helps them regulate DNA repair, researchers at Winship Cancer Institute of Emory University (Winship) have discovered.

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.